Market Research Logo

Myasthenia Gravis - Pipeline Review, H2 2018

Myasthenia Gravis - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Pipeline Review, H2 2018, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape.

Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking. Treatment includes immunosuppressants, corticosteroids and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myasthenia Gravis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Myasthenia Gravis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myasthenia Gravis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 7, 4 and 12 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Myasthenia Gravis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myasthenia Gravis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Myasthenia Gravis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myasthenia Gravis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myasthenia Gravis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myasthenia Gravis (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myasthenia Gravis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myasthenia Gravis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Myasthenia Gravis - Overview
Myasthenia Gravis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myasthenia Gravis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myasthenia Gravis - Companies Involved in Therapeutics Development
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alpha Cancer Technologies Inc
arGEN-X BV
BioMarin Pharmaceutical Inc
Bristol-Myers Squibb Co
CuraVac Inc
GlaxoSmithKline Plc
Grifols SA
GT Biopharma Inc
HanAll Biopharma Co Ltd
ImCyse SA
Millennium Pharmaceuticals Inc
Neurotune AG
Novartis AG
Pfizer Inc
Protalex Inc
Ra Pharmaceuticals Inc
Toleranzia AB
Tolerion Inc
UCB SA
Myasthenia Gravis - Drug Profiles
(ondansetron + pyridostigmine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abatacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amifampridine phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Agonize Aryl Hydrocarbon Receptor for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bortezomib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CFZ-533 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVMG-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
efgartigimod alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GL-2045 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
methotrexate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-1654 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRTX-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RA-101495 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ravulizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rozanolixizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TK-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOL-3034 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Myasthenia Gravis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myasthenia Gravis - Dormant Projects
Myasthenia Gravis - Discontinued Products
Myasthenia Gravis - Product Development Milestones
Featured News & Press Releases
Jun 13, 2018: Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer
Jun 12, 2018: Protalex Announces Lead Drug Candidate PRTX-100 Reduces Disease Activity in a Mouse Model of Myasthenia Gravis
Jun 06, 2018: argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis
Apr 24, 2018: argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting
Apr 23, 2018: Toleranzias CEO Charlotte Fribert on Antigen-Specific Immune Tolerance Drug Development Summit
Apr 19, 2018: Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse in MuSK Antibody Positive Myasthenia Gravis
Apr 09, 2018: argenx appoints Keith Woods as Chief Operating Officer
Apr 03, 2018: argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting
Mar 26, 2018: GT Biopharma Announces Additional Positive Data From Its Phase 1 Clinical Trial For Myasthenia Gravis and Potential for Acceleration of the Start of Its Phase 2 Trial
Mar 26, 2018: argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe
Jan 09, 2018: GT Biopharma Announces Completion of Dosing in Phase I Clinical Trial of GTP-004 for Myasthenia Gravis
Jan 08, 2018: Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment
Dec 21, 2017: Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients
Dec 11, 2017: argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
Dec 06, 2017: GT Biopharma Starts FDA Phase 1 Clinical Trial for Myasthenia Gravis Autoimmune Muscular Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Myasthenia Gravis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Myasthenia Gravis - Pipeline by Akari Therapeutics Plc, H2 2018
Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, H2 2018
Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, H2 2018
Myasthenia Gravis - Pipeline by arGEN-X BV, H2 2018
Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, H2 2018
Myasthenia Gravis - Pipeline by Bristol-Myers Squibb Co, H2 2018
Myasthenia Gravis - Pipeline by CuraVac Inc, H2 2018
Myasthenia Gravis - Pipeline by GlaxoSmithKline Plc, H2 2018
Myasthenia Gravis - Pipeline by Grifols SA, H2 2018
Myasthenia Gravis - Pipeline by GT Biopharma Inc, H2 2018
Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, H2 2018
Myasthenia Gravis - Pipeline by ImCyse SA, H2 2018
Myasthenia Gravis - Pipeline by Millennium Pharmaceuticals Inc, H2 2018
Myasthenia Gravis - Pipeline by Neurotune AG, H2 2018
Myasthenia Gravis - Pipeline by Novartis AG, H2 2018
Myasthenia Gravis - Pipeline by Pfizer Inc, H2 2018
Myasthenia Gravis - Pipeline by Protalex Inc, H2 2018
Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, H2 2018
Myasthenia Gravis - Pipeline by Toleranzia AB, H2 2018
Myasthenia Gravis - Pipeline by Tolerion Inc, H2 2018
Myasthenia Gravis - Pipeline by UCB SA, H2 2018
Myasthenia Gravis - Dormant Projects, H2 2018
Myasthenia Gravis - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Myasthenia Gravis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report